出生前親子鑑定

MiSeq FGx System and Prenatal Paternity Testing

ハート

↓今すぐDNA出生前親子鑑定を予約する↓

簡単WEB予約はこちら

What is the MiSeq FGx System?

The MiSeq FGx System is a Next-Generation Sequencer (NGS) developed by Illumina, specifically designed for forensic applications. It has the capability to analyze DNA sequences with high precision and speed, making it a crucial tool in criminal investigations and forensic genetics.

Prenatal Paternity Testing

Prenatal paternity testing is a method used to confirm the genetic relationship between a fetus and the father by analyzing the fetus’s DNA during pregnancy. This process typically involves using a blood sample from the mother to obtain the fetus’s DNA in a non-invasive manner. The main advantage of prenatal paternity testing is the ability to establish paternity during pregnancy.

Application of the MiSeq FGx System in Prenatal Paternity Testing

The MiSeq FGx System offers high accuracy and reliability in prenatal paternity testing. Here are the methods and benefits detailed:

  1. Non-Invasive Sample Collection:
  • Prenatal paternity testing uses a blood sample from the mother, which contains cell-free fetal DNA (cffDNA). By analyzing this cffDNA, the fetus’s genetic information can be obtained. The MiSeq FGx System efficiently analyzes this cffDNA.
  1. High Precision DNA Analysis:
  • The MiSeq FGx System provides extremely accurate DNA sequencing. This allows for precise comparison between the fetus’s DNA and the suspected father’s DNA, making it possible to determine paternity with a high degree of certainty.
  1. Rapid Results:
  • The system is capable of generating large volumes of data quickly, providing rapid results. This is a crucial factor in prenatal paternity testing.
  1. Forensic Validation:
  • The MiSeq FGx System adheres to forensic standards such as ISO 18385, ensuring its reliability and consistency. This allows the results to be used as legal evidence.
  1. Automated Data Analysis:
  • Equipped with intuitive data analysis software, the system helps users easily interpret data and generate reports. This facilitates the quick and accurate delivery of prenatal paternity test results.

Conclusion

The MiSeq FGx System, as a next-generation sequencer specialized for forensic use, offers high-precision and rapid DNA analysis. In prenatal paternity testing, its benefits include non-invasive sample collection, precise analysis, and quick results, enabling reliable determination of paternity. This ensures that the confirmation of paternity during pregnancy is both legally and scientifically sound.

For more detailed information, please visit the official Illumina website.

医師監修 監修日：2024年8月5日

岡 博史 （おか ひろし）

医師・医学博士 ／ ヒロクリニック統括院長

YouTubeチャンネルなどを通じて、遺伝子やNIPT（新型出生前診断）についてわかりやすく発信しています。

略歴

  • 1996年 慶應義塾大学医学部 卒業
  • 2004年 慶應義塾大学 医学博士号 取得
  • 2005年 慶應義塾大学 皮膚科学教室 助手
  • 2008年 ヒロ皮フ形成クリニック 開業
  • 2009年 医療法人社団福美会 理事長
  • 2015年 医療法人社団福美会 理事

資格・所属

  • CAPラボディレクター
  • 日本皮膚科学会 皮膚科専門医
  • 日本医師会 産業医
  • 東京衛生検査所 指導監督医

発信・関連リンク

この記事は、 ヒロクリニックNIPPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。

医師監修 監修日：2024年8月5日

堤 修一 （つつみ しゅういち）

医師・医学博士 ／ ヒロクリニック博多駅前院 院長

略歴

  • 1993年 東京大学医学部医学科 卒業
  • 2016〜2019年 東京大学先端科学技術研究センター 准教授

発信・関連リンク

この記事は、 ヒロクリニックNIPPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。

Latest Articles

Supervisor of the article

Dr. Hiroshi Oka

Director of CAP Laboratory

Graduated from Keio University, Faculty of Medicine

Doctor of Medicine

Medical Doctor